Kelleher Financial Advisors Boosts Stock Position in AbbVie Inc. $ABBV

Kelleher Financial Advisors boosted its stake in shares of AbbVie Inc. (NYSE:ABBV) by 80.7% in the fourth quarter, Holdings Channel reports. The fund owned 11,903 shares of the company’s stock after purchasing an additional 5,315 shares during the period. Kelleher Financial Advisors’ holdings in AbbVie were worth $2,720,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Chelsea Counsel Co. purchased a new stake in shares of AbbVie during the third quarter worth approximately $26,000. Westend Capital Management LLC purchased a new position in AbbVie in the 4th quarter valued at $29,000. Texas Capital Bancshares Inc TX acquired a new position in AbbVie in the 3rd quarter valued at $31,000. Evolution Wealth Management Inc. acquired a new position in AbbVie in the 2nd quarter valued at $26,000. Finally, Caitlin John LLC purchased a new position in AbbVie during the 3rd quarter worth $33,000. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on ABBV shares. UBS Group lowered their target price on shares of AbbVie from $240.00 to $230.00 and set a “neutral” rating on the stock in a report on Thursday, February 5th. BMO Capital Markets reissued an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. HSBC raised AbbVie from a “hold” rating to a “buy” rating and upped their price objective for the stock from $225.00 to $265.00 in a report on Wednesday, December 10th. Sanford C. Bernstein reiterated a “market perform” rating on shares of AbbVie in a research report on Thursday, February 5th. Finally, Piper Sandler raised their target price on AbbVie from $289.00 to $299.00 and gave the company an “overweight” rating in a report on Wednesday, February 18th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, AbbVie currently has a consensus rating of “Moderate Buy” and an average target price of $253.15.

Insiders Place Their Bets

In other news, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the transaction, the executive vice president owned 38,137 shares of the company’s stock, valued at $8,771,510. The trade was a 36.98% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP David Ryan Purdue sold 5,230 shares of the business’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the sale, the senior vice president owned 2,654 shares in the company, valued at $619,868.24. This represents a 66.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 0.25% of the company’s stock.

AbbVie Trading Down 0.0%

ABBV stock opened at $208.79 on Friday. The firm has a 50 day moving average of $221.58 and a 200-day moving average of $224.47. The company has a market cap of $369.17 billion, a price-to-earnings ratio of 88.47, a PEG ratio of 0.73 and a beta of 0.38. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The business had revenue of $16.62 billion for the quarter, compared to analysts’ expectations of $16.39 billion. During the same quarter in the prior year, the firm posted $2.16 EPS. The company’s revenue was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Sell-side analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be given a $1.73 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.3%. AbbVie’s dividend payout ratio (DPR) is currently 293.22%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.